Sep 2, 2025 06:19AM H.C. Wainwright Assumes Inflarx NV (IFRX) at Buy

Jul 11, 2025 04:15PM InflaRx receives NASDAQ deficiency notice for minimum bid price

May 29, 2025 03:46AM Raymond James Downgrades Inflarx NV (IFRX) to Outperform

May 28, 2025 10:35AM Guggenheim Reiterates Buy Rating on Inflarx NV (IFRX)

May 28, 2025 04:55AM InflaRx N.V. (IFRX) Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 13, 2025 04:37PM Raymond James Reiterates Strong Buy Rating on Inflarx NV (IFRX), PT $13

Apr 29, 2025 06:32AM Cantor Fitzgerald Starts Inflarx NV (IFRX) at Overweight

Mar 26, 2025 06:57AM Inflarx NV (IFRX) PT Raised to $10 at Guggenheim

Feb 13, 2025 04:01PM InflaRx (IFRX) Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 16, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Inflarx NV (IFRX)

Jan 15, 2025 12:30PM InflaRx N.V. (IFRX) Receives European Commission Approval for GOHIBIC for the Treatment of SARS-CoV-2-Induced ARDS

Dec 23, 2024 07:11AM H.C. Wainwright Reiterates Buy Rating on Inflarx NV (IFRX)

Nov 19, 2024 08:07AM Lucid Capital Markets Starts Inflarx NV (IFRX) at Buy

Nov 15, 2024 07:52AM InflaRx (IFRX) Receives Positive CHMP Opinion for GOHIBIC for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Sep 26, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Inflarx NV (IFRX)

Sep 25, 2024 07:31AM InflaRx (IFRX) Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 3, 2024 07:30AM InflaRx N.V. (IFRX) Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 8, 2024 07:39AM InflaRx N.V. (IFRX) Misses Q2 EPS by 4c

Jun 24, 2024 08:04AM InflaRx N.V.'s (IFRX) GOHIBIC Selected for First BARDA-Sponsored Trial